JPS55145615A - Blood coagulation factor and its manufacture - Google Patents

Blood coagulation factor and its manufacture

Info

Publication number
JPS55145615A
JPS55145615A JP5609880A JP5609880A JPS55145615A JP S55145615 A JPS55145615 A JP S55145615A JP 5609880 A JP5609880 A JP 5609880A JP 5609880 A JP5609880 A JP 5609880A JP S55145615 A JPS55145615 A JP S55145615A
Authority
JP
Japan
Prior art keywords
manufacture
blood coagulation
coagulation factor
xiii
viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5609880A
Other languages
English (en)
Other versions
JPS6254286B2 (ja
Inventor
Shiyubuin Horusuto
Haimuburugaa Noruberuto
Kumupe Geruharuto
Heruhienhan Berunto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of JPS55145615A publication Critical patent/JPS55145615A/ja
Publication of JPS6254286B2 publication Critical patent/JPS6254286B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/851—Placenta; amniotic fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP5609880A 1979-04-25 1980-04-25 Blood coagulation factor and its manufacture Granted JPS55145615A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792916711 DE2916711A1 (de) 1979-04-25 1979-04-25 Blutgerinnungsfaktoren und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
JPS55145615A true JPS55145615A (en) 1980-11-13
JPS6254286B2 JPS6254286B2 (ja) 1987-11-13

Family

ID=6069217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5609880A Granted JPS55145615A (en) 1979-04-25 1980-04-25 Blood coagulation factor and its manufacture

Country Status (8)

Country Link
US (1) US4297344A (ja)
EP (1) EP0018561B1 (ja)
JP (1) JPS55145615A (ja)
AT (1) ATE22396T1 (ja)
DE (2) DE2916711A1 (ja)
DK (1) DK155568C (ja)
ES (1) ES8100884A1 (ja)
IL (1) IL59924A (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57193418A (en) * 1981-05-14 1982-11-27 Behringwerke Ag Manufacture of plasminogen
JPS58500548A (ja) * 1981-04-27 1983-04-14 バクスター、インターナショナル、インコーポレイテツド 新規な血液凝固酵素組成物の製造方法
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
JPS59206314A (ja) * 1983-05-02 1984-11-22 イムノ・アクチエンゲゼルシャフト 血液製剤中の病原体不活化法
JPS62283931A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The プラスミノ−ゲンの安定化方法
JPS6323896A (ja) * 1986-07-11 1988-02-01 マイルス・ラボラトリ−ス・インコ−ポレ−テツド ウイルスの不活性化および活性蛋白質の精製
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
WO1991000739A1 (fr) * 1989-07-07 1991-01-24 Kyowa Hakko Kogyo Co., Ltd. Preparation de motiline stable
JPH08245418A (ja) * 1995-03-09 1996-09-24 Behringwerke Ag 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
JP2000509374A (ja) * 1996-04-19 2000-07-25 アルファ セラピュティック コーポレイション 凍結乾燥した血液タンパク質のウイルス不活性化方法
JP2002112765A (ja) * 2000-08-01 2002-04-16 Nihon Pharmaceutical Co Ltd ウイルス不活化法
JP2009077707A (ja) * 1995-07-14 2009-04-16 Sartorius Stedim Biotech Gmbh 血液製剤中の汚染物質を不活性化する方法
WO2019182123A1 (ja) * 2018-03-23 2019-09-26 味の素株式会社 トランスグルタミナーゼを含有する液体製剤

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
IT1194135B (it) * 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
US4480029A (en) * 1981-04-27 1984-10-30 Baxter Travenol Laboratories, Inc. Biological indicators and their use
EP0286198B1 (en) * 1981-04-27 1994-12-14 BAXTER INTERNATIONAL INC. (a Delaware corporation) Blood clotting enzyme compositions
WO1982004395A1 (en) * 1981-06-18 1982-12-23 Erik Gustaf Birger Blombaeck A process in purification and concentration of the factor viii complex
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4845074A (en) * 1982-05-13 1989-07-04 Cedars Sinai Medical Center Heat treatment of Factor VIII
US4556558A (en) * 1982-05-13 1985-12-03 Cedars-Sinai Medical Center Treatment of factor VIII concentrate to minimize the affect of undesirable microorganisms
DE3230849A1 (de) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
DE3473407D1 (en) * 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
HUT40311A (en) * 1983-06-03 1986-12-28 Kiskunhalasi Aag Process for producing protein concentrates, blood-curd and nutriments from blood and its elements
DE3330770A1 (de) * 1983-08-26 1985-03-14 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von humanplasma
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
AT390001B (de) * 1984-09-28 1990-03-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
DE3602688A1 (de) * 1986-01-30 1987-08-06 Behringwerke Ag Verfahren zur gewinnung und herstellung eines pasteurisierten praeparates von (alpha)(pfeil abwaerts)2(pfeil abwaerts)-antiplasmin
DE3621371A1 (de) * 1986-03-12 1987-09-17 Behringwerke Ag Gentechnische herstellung von faktor xiiia
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
CA1310267C (en) * 1986-07-09 1992-11-17 Yutaka Hirao Process for heat treating chemically unmodified _-globulin
DE3625090A1 (de) * 1986-07-24 1988-01-28 Behringwerke Ag Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
AU2423988A (en) * 1987-08-17 1989-03-09 Liposome Company, Inc., The A sponge enzyme having transglutaminase-like activity
DK18288D0 (da) * 1988-01-15 1988-01-15 Nordisk Gentofte Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
FR2650508A1 (fr) * 1989-08-01 1991-02-08 Fondation Nale Transfusion San Colle pasteurisee pour reunir des tissus humain ou animal
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤
JPH0813750B2 (ja) * 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
FR2664165B1 (fr) 1990-07-03 1992-10-16 Lille Transfusion Sanguine Composition pour stabiliser le plasma sanguin en cours de pasteurisation.
US5314695A (en) † 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
WO1994013329A1 (de) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
US5589167A (en) * 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
KR100330540B1 (ko) * 1993-04-05 2002-09-04 웰파이드 코포레이션 안티트롬빈-iii액상제제및그안정화방법
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
EP0771324B2 (fr) * 1994-07-14 2011-02-09 CAF-DCF Département Central de Fractionnement de la Croix Rouge S.C.R.L. Concentre de fibrinogene issu de plasma sanguin, procede et installation pour sa preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US6030821A (en) * 1994-10-11 2000-02-29 Ajinomoto Co., Inc. Stabilized transglutaminase and enzyme preparation containing the same
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
JPH08333277A (ja) * 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5989593A (en) * 1996-11-20 1999-11-23 Yoshitomi Pharmaceutical Industries, Ltd. Method for producing antithrombin-III, method for purifying it, and preparation containing it
GB9711927D0 (en) * 1997-06-09 1997-08-06 Bristol Myers Squibb Co Compositions useful as fibrin sealants
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
AT407484B (de) * 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
DE19856443A1 (de) 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
US6733985B1 (en) * 1999-05-19 2004-05-11 International Technidyne Corporation Preparation of stable liquid and dried synthetic prothrombin time reagents
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
EP1232174B1 (en) 1999-11-18 2013-05-01 Ischemix, Inc Compositions and methods for counteracting effects of reactive oxygen species and free radicals
MXPA02006762A (es) 2000-01-28 2002-10-23 Aventis Pharma Gmbh Proceso para la preparacion de acetil-amidinoifenilalanil -ciclohexilglicil -piridinoalaninamidas.
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
CA2406790C (en) 2000-04-19 2009-07-07 Genentech, Inc. Sustained release formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20020176796A1 (en) * 2000-06-20 2002-11-28 Purepulse Technologies, Inc. Inactivation of microbes in biological fluids
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
AU2002242231B2 (en) * 2001-02-23 2007-09-06 Genentech, Inc. Erodible polymers for injection
JP2004536062A (ja) * 2001-05-17 2004-12-02 セレメディックス，インク． 反応性酸素種およびフリーラジカルの効力を中和するためのペプチド化合物
ES2554106T3 (es) * 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
WO2003055511A1 (en) * 2001-12-21 2003-07-10 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
IL162239A0 (en) * 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
MXPA05009914A (es) * 2003-03-18 2006-01-09 Novo Nordisk Healthcare Ag Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
US7498130B2 (en) * 2003-05-13 2009-03-03 Massachusetts General Hospital Method of reducing viral load
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
EP2298287B1 (en) * 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
WO2006110819A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
SG10201706384VA (en) * 2005-04-11 2017-09-28 Crealta Pharmaceuticals Llc A variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20090081122A1 (en) * 2005-05-23 2009-03-26 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
EP1913159B1 (en) * 2005-06-30 2010-12-01 GE Healthcare Bio-Sciences Corp. Detection method for gene expression
ES2532804T3 (es) 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
KR101710471B1 (ko) * 2008-04-21 2017-02-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 건조한 트랜스글루타미나제 조성물
CN102202682B (zh) 2008-11-04 2015-08-19 Aska制药株式会社 含促卵泡激素的水性组合物
AU2009313325B2 (en) * 2008-11-07 2014-05-01 Takeda Pharmaceutical Company Limited Factor VIII formulations
BRPI1010069A2 (pt) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
EP2563809B1 (en) 2010-04-27 2020-04-01 Scil Technology GmbH Stable aqueous mia/cd-rap formulations
IL213864A0 (en) 2011-06-30 2011-08-31 Omrix Biopharmaceuticals Ltd Method for removing a lytic enzyme from a heterogeneous mixture
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
RU2556804C2 (ru) * 2013-12-17 2015-07-20 Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ Способ получения концентрата фибриногена
IL231230A0 (en) 2014-02-27 2014-08-31 Omrix Biopharmaceuticals Ltd Fibrinogen preparation
BR112016025126B1 (pt) 2014-05-07 2024-02-15 Takeda Pharmaceutical Company Limited Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
LT3233111T (lt) 2014-12-19 2024-10-10 Kedrion Biopharma Inc. Farmacinė kompozicija, apimanti plazminogeną, ir jos panaudojimas
IL247821A0 (en) 2016-09-14 2017-01-31 Omrix Biopharmaceuticals Ltd Adhesive preparations and their use
IL263679A (en) 2018-12-12 2019-03-31 Omrix Biopharmaceuticals Ltd Kits, methods, and ingredients for preventing tissue adhesion
WO2020121290A1 (en) 2018-12-12 2020-06-18 Omrix Biopharmaceuticals Ltd. High concentrated protein compositions for preventing tissue adhesion
WO2023119277A1 (en) 2021-12-21 2023-06-29 Omrix Biopharmaceuticals Ltd. Highly soluble fibrinogen compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS502039A (ja) * 1973-05-07 1975-01-10
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3066079A (en) * 1959-09-18 1962-11-27 American Cyanamid Co Methods for purifying plasminogen
GB941019A (en) * 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
US3227626A (en) * 1961-09-18 1966-01-04 Merck & Co Inc Plasminogen heat sterilization
CA958339A (en) * 1970-09-19 1974-11-26 Yoshio Yoshimura Stabilization of microorganism cells lytic enzyme
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US3732146A (en) * 1970-12-22 1973-05-08 Behringwerke Ag Process for the isolation of native, highly purified plasminogen
SE392038B (sv) 1971-09-08 1977-03-14 Kabi Ab Forfarande for isolering av antitrombin ur blod eller blodprodukter
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
JPS51118820A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable macroglobulin
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
JPH05118819A (ja) * 1991-10-29 1993-05-14 Toshiba Corp 視覚認識装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS502039A (ja) * 1973-05-07 1975-01-10
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58500548A (ja) * 1981-04-27 1983-04-14 バクスター、インターナショナル、インコーポレイテツド 新規な血液凝固酵素組成物の製造方法
JPS57193418A (en) * 1981-05-14 1982-11-27 Behringwerke Ag Manufacture of plasminogen
JPH0366292B2 (ja) * 1981-05-14 1991-10-16 Behringwerke Ag
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
JPS6237010B2 (ja) * 1983-01-20 1987-08-10 Green Cross Corp
JPH0585524B2 (ja) * 1983-05-02 1993-12-07 Immuno Ag
JPS59206314A (ja) * 1983-05-02 1984-11-22 イムノ・アクチエンゲゼルシャフト 血液製剤中の病原体不活化法
JPS62283931A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The プラスミノ−ゲンの安定化方法
JPS6323896A (ja) * 1986-07-11 1988-02-01 マイルス・ラボラトリ−ス・インコ−ポレ−テツド ウイルスの不活性化および活性蛋白質の精製
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
WO1991000739A1 (fr) * 1989-07-07 1991-01-24 Kyowa Hakko Kogyo Co., Ltd. Preparation de motiline stable
JPH08245418A (ja) * 1995-03-09 1996-09-24 Behringwerke Ag 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
JP2009077707A (ja) * 1995-07-14 2009-04-16 Sartorius Stedim Biotech Gmbh 血液製剤中の汚染物質を不活性化する方法
JP2000509374A (ja) * 1996-04-19 2000-07-25 アルファ セラピュティック コーポレイション 凍結乾燥した血液タンパク質のウイルス不活性化方法
JP2002112765A (ja) * 2000-08-01 2002-04-16 Nihon Pharmaceutical Co Ltd ウイルス不活化法
WO2019182123A1 (ja) * 2018-03-23 2019-09-26 味の素株式会社 トランスグルタミナーゼを含有する液体製剤

Also Published As

Publication number Publication date
EP0018561B1 (de) 1986-09-24
EP0018561A2 (de) 1980-11-12
DE3071773D1 (en) 1986-10-30
IL59924A (en) 1983-06-15
ES490682A0 (es) 1980-12-01
ES8100884A1 (es) 1980-12-01
DK176280A (da) 1980-10-26
EP0018561A3 (en) 1981-10-21
IL59924A0 (en) 1980-06-30
DK155568B (da) 1989-04-24
DK155568C (da) 1989-10-09
ATE22396T1 (de) 1986-10-15
US4297344A (en) 1981-10-27
DE2916711A1 (de) 1980-11-06
JPS6254286B2 (ja) 1987-11-13

Similar Documents

Publication Publication Date Title
JPS55145615A (en) Blood coagulation factor and its manufacture
BR8207582A (pt) Processo para producao de novas composicoes de enzima para coagulacao sang"uinea
NO830110L (no) 6-substituert-s-triazolo(3,4-a)ftalazinderivater og fremgangsmaate for deres fremstilling
PT76546A (en) Process for preparing functional human urokinase protein
NO159698C (no) Fremgangsm te til pasteurisering av human-fibrinoge
NO893637D0 (no) Fremgangsmaate for aa stabilisere blodkoagulasjonsfaktorer.
DK398185A (da) Pasteuriseret, hoejrenset faktor viii-praeparat og fremgangsmaade til fremstilling deraf
ES535409A0 (es) Procedimiento para pasterizar un plasma de radical-humano
GR851065B (ja)
DE2965532D1 (en) Process for obtaining blood coagulation factor xiii derived from human placenta
NO174415C (no) Spannlegeme, samt fremgangsmåte for dets tilvirkning
SE7708780L (sv) Fluorsulfonyloxafluoroalkaner, deras derivat, fluorosulfonylolefiner, deras sampolymerer och forfarande for framstellning derav
NO831632L (no) Fremgangsmaate for fremstilling av substituerte imidazolyl-tiazol-derivater.
DE3067643D1 (en) Protein pp 11, process for its isolation and its use
HUT36783A (en) Process for preparing 1,7-diphenyl-3-methyl-aza-7-cyano-8-methyl-nonane
CA1034570A (en) Process for coagulating protein
FI841199A (fi) Foerfarande foer stabilisering av hematin.
ES8203572A3 (es) Procedimiento e instalacion para el tratamiento de champino-nes
AU490311B2 (en) Process for coagulating protein
KR790000054B1 (en) Isolation of orgotein
IT8023483V0 (it) Macchina per il trattamento di calzature mediante riscaldamento, umidificazione e vuoto.
IT7819169A0 (it) Procedimento per la fabbricazione di calze-mutande, macchina circolare per l'attuazione del procedimento e prodotto ottenuto.
ES430745A1 (es) Procedimiento para la obtencion de albumina a partir de plasma humano.
IT8445729A0 (it) Procedimento di decolorazione del legno, impianto utilizzato per eseguire tale procedimento eprodotto cosi' ottenuto.